NNMTi? is a substrate site-targeting, selective nicotinamide N-methyltransferase (NNMT) inhibitor (IC50 = 1.2 μM;?50 μM SAM, 100 μM NCA) that reduces 3T3-L1 lipogenesis (EC50 = 30μM) and adipocytes 1-methylnicotinamide level (EC50 = 2.3 μM) without affecting related methyltransferases & enzymes in the NAD+ salvage pathwayNNMTi treatment will rescue age-related deficits in muSC activity to promote superior regeneration post-injury in aging muscle.

Pipemidic scid is a new antibacterial agent, is active against Pseudomonas aeruginosa.

Pimonidazole accumulates in hypoxic cells via covalent binding with macromolecules or by forming reductive metabolites after the reduction of its nitro group.